Article Per Year (5 Year)
p-Index From 2020 - 2025
0.61
P-Index
This Author published in this journals
All Journal Narra J Ophthalmologica Indonesiana
Kurniawan, Chalid
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Public Health

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
Short-term outcomes of implanting a retropupillary iris-claw intraocular lens in patients with lens and intraocular lens drops Kurniawan, Chalid; Kartasasmita, Arief S.; Harley, Ohisa
Narra J Vol. 4 No. 2 (2024): August 2024
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v4i2.892

Abstract

Lens drop and intraocular lens (IOL) drop can occur after cataract or phacoemulsification surgery, where the IOL is dislocated from the capsular bag into the vitreous cavity. The aim of this study was to investigate the short-term outcomes of implanting a retropupillary iris claw in patients with IOL drop and lens drop after phacoemulsification. A cross-sectional study was conducted at Santosa Hospital, Bandung, West Java, Indonesia, from January 2020 to December 2023. Patients were divided into two groups: IOL drop and lens drop groups. Total sampling was used, involving 51 patients in the present study, with 27 patients in the IOL drop group and 24 patients in the lens drop group. Data collected included age, sex, eye laterality, the onset of IOL drop or lens drop, intraocular pressure (IOP), uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), record of astigmatism change preoperative and postoperative, and postoperative pars plana vitrectomy (PPV) complications. Our data indicated that the UDVA significantly improved in both IOL drop and lens drop groups after PPV surgery (p<0.001). However, there were no significant changes in IOP or astigmatism following the surgery in either group. Over one month, both groups showed improved UDVA, decreased IOP, and changes in astigmatism, with no significant differences between groups. Similarly, there was no significant difference in CDVA between IOL drop and lens drop groups. Only four complications were recorded in the present study. Comparing IOL drop and lens drop groups, only an increase in IOP showed a significant difference (p=0.018). Corneal edema, IOL decentration, and pupil ovalization were not significantly different. In conclusion, retropupillary iris-claw IOL implantation is safe and effective for aphakic patients with complications from phacoemulsification, regardless of whether it is lens drop or IOL drop.
Bevacizumab vs Ranibizumab in Macular Edema due to Retinal Vein Occlusion: Short-term Outcomes KURNIAWAN, CHALID
Majalah Oftalmologi Indonesia Vol 49 No S2 (2023): Supplement Edition
Publisher : The Indonesian Ophthalmologists Association (IOA, Perhimpunan Dokter Spesialis Mata Indonesia (Perdami))

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35749/vvcfz739

Abstract

Introduction & ObjectivesBevacizumab or Ranibizumab was widely used as therapy for macular edema (ME) in retinal veinocclusion (RVO) and diabetic retinopathy. The purpose of this study was to comparing short-termoutcomes for patients who received intravitreal Bevacizumab (IVB) injection or Ranibizumab (IVR)for ME due to RVO MethodsThis was observational, cross sectional study comparing patients received IVB or IVR. Primaryoutcomes data (visual acuity and central macular thickness/CMT) and secondary outcomes data(number injection and intra ocular pressure/IOP) were collected at baseline and 3 months afterinjection ResultsThere were 4 eyes in each group. There were no significant difference in mean change of visualacuity (-0.275±0.25 vs -0.15±0.5 logMAR; p=0.676) and CMT (-171.50±129.08 vs -98.25±37.67 um;p=0.345) in IVB vs IVR groups. There were also no significant difference in mean change of IOP(2±2.16 vs 2±4.69 mmHg; p=1) and number of injection (2.25±0.50 vs 1.75±0.9; p=0.401 ) in bothgroups. ConclusionIn short-term both IVB and IVB have relative similar outcomes on increasing visual acuity anddecreasing CMT in ME due to RVO
BEVACIZUMAB VS RANIBIZUMAB IN MACULAR EDEMA DUE TO RETINAL VEIN OCCLUSION: SHORT-TERM OUTCOMES Kurniawan, Chalid
Majalah Oftalmologi Indonesia Vol 50 No 2 (2024): Ophthalmologica Indonesiana
Publisher : The Indonesian Ophthalmologists Association (IOA, Perhimpunan Dokter Spesialis Mata Indonesia (Perdami))

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35749/tef09433

Abstract

Introduction and Objective: Bevacizumab or Ranibizumab was widely used as therapy for macular edema (ME) in retinal vein occlusion (RVO) and diabetic retinopathy. The purpose of this study was to comparing short-term outcomes for patients who received intravitreal Bevacizumab (IVB) injection or Ranibizumab (IVR) for ME due to RVO Methods: This was observational, cross sectional study comparing patients received IVB or IVR. Primary outcomes data (visual acuity and central macular thickness/CMT) and secondary outcomes data (number injection and intra ocular pressure/IOP) were collected at baseline and 3 months after injection Results: There were 4 eyes in each group. There were no significant difference in mean change of visual acuity (-0.2750.25 vs -0.150.5 logMAR; p=0.676) and CMT (-171.50 129.08 vs -98.2537.67 m; p=0.345) in IVB vs IVR groups. There were also no significant difference in mean change of IOP (22.16 vs 24.69 mmHg; p=1) and number of injection (2.250.50 vs 1.750.9; p=0.401 ) in both groups.   Conclusion: In short-term both IVB and IVB have relative similar outcomes on increasing visual acuity and decreasing CMT in ME due to RVO
Co-Authors Arief S. Kartasasmita Harley, Ohisa